This company listing is no longer active
2Q3A Stock Overview
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
9 Meters Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.24 |
| 52 Week High | US$6.40 |
| 52 Week Low | US$0.24 |
| Beta | 1.48 |
| 11 Month Change | -62.84% |
| 3 Month Change | -81.24% |
| 1 Year Change | -94.67% |
| 33 Year Change | -97.41% |
| 5 Year Change | n/a |
| Change since IPO | -97.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2Q3A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -60.0% | -1.2% | -0.02% |
| 1Y | -94.7% | -20.1% | 8.2% |
Return vs Industry: 2Q3A underperformed the German Pharmaceuticals industry which returned -10% over the past year.
Return vs Market: 2Q3A underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 2Q3A volatility | |
|---|---|
| 2Q3A Average Weekly Movement | 19.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 2Q3A's share price has been volatile over the past 3 months.
Volatility Over Time: 2Q3A's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 10 | Bethany Sensenig | www.9meters.com |
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease.
9 Meters Biopharma, Inc. Fundamentals Summary
| 2Q3A fundamental statistics | |
|---|---|
| Market cap | €8.01m |
| Earnings (TTM) | -€41.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs 2Q3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2Q3A income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$46.28m |
| Earnings | -US$46.28m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -80.5% |
How did 2Q3A perform over the long term?
See historical performance and comparison